Ovarian cancer is a deadly disease with few effective therapies. The most common form is
high-grade serous ovarian cancer (HGSOC). Transcriptomic subtypes of HGSOC have shown …

Hormone receptor (HR) positive breast cancers, which account for approximately 75% of all
breast cancers and express both estrogen receptor (ER) and progesterone receptor (PR), …

One of the oldest and most common therapies for endometrial complex atypical hyperplasia
(CAH) and low-stage, low-grade endometrioid endometrial carcinoma (EEC) is the use of …

Serous endometrial and ovarian cancers represent significant morbidity and mortality for
gynecologic cancers due to the high rate of resistance to chemotherapy and recurrence after …

Mammalian genomes encode an order of magnitude more gene expression enhancers than
promoters, suggesting that most genes are regulated by combinations of enhancers. We …

Progesterone prevents development of endometrial cancers through its receptor (PR) although
the molecular mechanisms have yet to be fully characterized. In this study, we performed …

… Soisson, Jay Gertz. Identification of differentially expressed genes in primary samples of
endometrial hyperplasia and endometrioid endometrial carcinoma responsive to progestin …

… 2nd year (1st year in the Gertz lab). Spencer joined the Gertz lab in May and has devoted all
of … Working on this collaborative project between the Richer and Gertz labs has provided her …

Estrogen signaling through estrogen receptor alpha (ER) is considered to be a driving oncogenic
signal in type 1 endometrial cancer. However, excess estrogen exposure isn’t sufficient …

Sex can be an important determinant of cancer phenotype and exploring sex-specific tumor
biology holds promise for identifying novel therapeutic targets and new approaches to …